metricas
covid
Buscar en
Open Respiratory Archives
Toda la web
Inicio Open Respiratory Archives Severe Eosinophilic Asthma and Severe Mixed Polyneuropathy: A Case of Eosinophil...
Journal Information
Vol. 6. Issue 2.
(April - June 2024)
Share
Share
Download PDF
More article options
Visits
543
Vol. 6. Issue 2.
(April - June 2024)
Scientific Letter
Full text access
Severe Eosinophilic Asthma and Severe Mixed Polyneuropathy: A Case of Eosinophilic Granulomatous Vasculitis With Polyangiitis and New Therapeutic Perspectives
Asma eosinofílica grave y polineuropatía mixta severa. Un nuevo caso de vasculitis granulomatosa eosinofílica con poliangeítis (GEPA). Nuevas perspectivas terapéuticas
Visits
543
María del Carmen Lorenzo Martíneza, Ángela Hidalgo Herranza, Ana María Ochoa Ruiza, Bárbara Gutierrez Ruanob, Raúl Ruiz Estebanc, Sergio Campos Télleza, José Javier Jareño Estebana,
Corresponding author
jjjarenoesteban@yahoo.es

Corresponding author.
a Respiratory Medicine Department, Hospital Central de la Defensa Gómez Ulla, Madrid, Spain
b Neurology Department, Hospital Central de la Defensa Gómez Ulla, Madrid, Spain
c Internal Medicine Department, Hospital Central de la Defensa Gómez Ulla, Madrid, Spain
This item has received
Article information
Full Text
Bibliography
Download PDF
Statistics
Tables (1)
Table 1. Clinical and functional comparison before and after starting mepolizumab treatment.
Full Text
Dear Editor,

We report the case of a 46-year-old woman, non-smoker with a history of severe uncontrolled asthma. Since the age of 30, she has presented symptoms of arthralgia and myalgia, and 2 years ago she developed distal paraesthesia. Physical examination revealed diffuse bilateral wheezing on pulmonary auscultation. Neurological findings included right-sided peripheral hypoesthesia. Laboratory values of note included haemoglobin 11.3g/dl, haematocrit 37.2%, and eosinophils 485 (6.9%). Kidney function, ionogram and thyroid hormones were normal. Antineutrophil cytoplasmic antibody (ANCA) testing, an immunological study for connective tissue diseases and serologies were all negative. Chest computed tomography showed pulmonary opacities in the left upper lobe. Sural nerve biopsy led to a diagnosis of eosinophilic granulomatosis with polyangiitis (EGPA). The Birmingham activity score was 10 points. Treatment began with corticosteroids and cyclophosphamide that, due to adverse effects, were switched to azathioprine. At follow-up, paraesthesia had progressed so we changed treatment to rituximab and continued with prednisone. In the following months, worsening asthma control (Asthma Control Test<15, reduced forced expiratory volume in 1 second, elevated fractional exhaled nitric oxide) and progression of neurological symptoms were observed. In view of this situation, inhaled therapy and systemic corticosteroids were optimised. We also started mepolizumab at 100mg that was progressively increased to 300mg to achieve greater control of EGPA activity, asthma, and improve pulmonary function and neurological symptoms (Table 1). Subsequently, we were able to reduce corticosteroid dosage.

Table 1.

Clinical and functional comparison before and after starting mepolizumab treatment.

  Without mepolizumab treatment  With mepolizumab treatment 
Asthma exacerbation  6 per year  None 
ACT  10  23 
Spirometry
FVC  3040mL (128%)  2240mL (99%) 
FEV1  1280mL (64%)  1720mL (91%) 
FEV1/FVC  0.42  0.74 
Prednisone dose  15mg  5mg 

ACT: asthma control test; FEV1: forced expiratory volume in 1 second; FVC: forced vital capacity.

EGPA is characterised by eosinophilic tissue infiltration associated with vasculitis and the presence of granulomas. Clinical manifestations are varied, and diagnostic criteria include asthma, rhinosinusitis, peripheral blood eosinophilia, extravascular eosinophilia, evanescent pulmonary infiltrates, and peripheral neuropathy. Only 40% of patients are ANCA-positive. The Birmingham activity score (≥4) is currently used to assess the degree of activity and remission.1 The survival of patients with vasculitis has increased in recent decades due to the use of immunomodulators and corticosteroids, but these treatments are not exempt from toxicity or risk of infections. In recent years, new treatments such as rituximab and mepolizumab have appeared and have demonstrated their efficacy in inducing remission.

Rituximab is an anti-CD20 monoclonal antibody that depletes B-lymphocytes and has shown efficacy in microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). Experience in EGPA is scant but growing, with the recent publication of several series in EGPA patients in which rituximab demonstrated efficacy in controlling disease activity and possibly reducing maintenance doses of corticosteroids.2,3

In our patient, refractory vasculitis and mononeuritis multiplex improved partially with rituximab treatment. However, persistent neurological symptoms and poor asthma control prompted the initiation of mepolizumab associated with corticosteroids as an alternative to other treatments (methotrexate, azathioprine and mycophenolate mofetil, etc.). Recent multicentre studies in Europe have confirmed the efficacy and safety of this combination. It is well tolerated and is associated few adverse effects and a low risk of infections, allowing a progressive reduction of the corticosteroid dose.4 Several European studies show that a 100mg dose of mepolizumab is as effective as the 300mg dose recommended by the US Food and Drug Administration.5

Informed consent

The authors have obtained the informed consent of the patient and/or subjects referred to in the article. This document is held by the corresponding author.

Funding

No external financing was needed for this study.

Authors’ contributions

All authors have contributed substantially to each of the following aspects: (1) data acquisition, data analysis and interpretation, (2) drafting of the article, and (3) final approval of the version presented.

Conflicts of interests

The authors state that they have no conflict of interests.

References
[1]
S.A. Chung, C.A. Langford, M. Maz, A. Abril, M. Gorelik, G. Guyarr, et al.
2021 American College of Rheumatology/Vasculitis Foundation Guideline for the management of antineutrophil cytoplasmic antibody – associated vasculitis.
Arthritis Care Res, 73 (2021), pp. 1088-1105
[2]
G. Emmi, G.M. Rossi, L.M. Urban, E. Silvestri, D. Prisco, M. Goldoni, et al.
Scheduled rituximab maintenance reduces relapse rate in eosinophilic granulomatosis with polyangiitis.
Ann Rheum Dis, 77 (2018), pp. 952-954
[3]
V. Teixeira, A.J. Mohammad, R.B. Jones, R. Smith, D. Jayne.
Efficacy and safety or rituximab in the treatment of eosinophilic granulomatosis with polyangitis.
RMD Open, 5 (2019), pp. e000905
[4]
M. Ueno, I. Miyagawa, T. Aeitomi, K. Kimura, S. Iwata, K. Hanami, et al.
Safety and effectiveness of mepolizumab therapy in remission induction therapy for eosinophilic granulomatosis with polyangiitis: a retrospective study.
Arthritis Res Therapy, (2022), pp. 159
[5]
A. Vultaggio, F. Nencini, S. Bormioli, E. Vivarelli, L. Dies, O. Rossi, et al.
Low dose mepolizumab effectiveness in patients suffering from eosinophilic granulomatosis with polyangiitis.
Allergy Asmthma Immunol Res, 12 (2020), pp. 885-893
Copyright © 2024. Sociedad Española de Neumología y Cirugía Torácica (SEPAR)
Download PDF
Article options
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.opresp.2022.100188
No mostrar más